DCGI approves India's first qHPV vaccine to treat cervical cancer

Category : National Published on: July 14 2022

Share on facebook

Drugs Controller General of India (DCGI) granted market authorisation to Serum Institute of India (SII) to manufacture indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer.
Cervical cancer is the second most frequent cancer among women between 15 and 44 years of age with a high death ratio in India.
The approval by the drug regulator of SII’s anti-cancer vaccine followed recommendation by the Subject Expert Committee (SEC) on COVID-19 of the CDSCO on June 15.
Earlier the Serum Institute had applied to the DCGI seeking market authorisation of the qHPV after the phase 2/3 clinical trial was completed with support of the Department of Biotechnology.